There are currently no expansion plans for the Active Pharmaceutical Ingredient Business. CSPC Innovation Pharmaceutical is expected to receive the first installment of the BD payment in the first half of this year | Focus on the Earnings Conference.

① In the future, CSPC Innovation Pharmaceutical will continue to explore SYS6010 (EGFR ADC) for indications such as gastrointestinal cancer. ② CSPC Innovation Pharmaceutical has reviewed the progress of its GLP-1 products, stating that some MNCs have already expressed interest in the company's related varieties. ③ The Active Pharmaceutical Ingredient business is currently focused on cost reduction through process technology upgrades, with no plans for expansion at this time.

cls.cnMar 21 09:02 ET

"Burned" over 0.8 billion yuan in R&D expenses, CSPC Innovation Pharmaceutical experiences a decline in revenue and net profit | Interpretations

① The functional foods and ingredients business segment experienced a decrease in main business revenue while research and development expenses significantly increased, resulting in declines in revenue and Net income for CSPC Innovation Pharmaceutical in 2024. ② In 2024, the company achieved certain results in the field of Innovative Drugs.

cls.cnMar 20 11:22 ET

Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the

① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.

cls.cnMar 2 21:09 ET

Another "miracle drug for myopia" application has been accepted, will Shenyang Xingqi Pharmaceutical's "star product" be impacted? | Quick announcement review

①The application for marketing authorization of HR19034 eye drops under Jiangsu Hengrui Pharmaceuticals has been accepted by the National Medical Products Administration, challenging the exclusive position of Shenyang Xingqi Pharmaceutical. ② The atropine sulfate eye drops suitable for myopia in adolescents under several pharmaceutical companies have all entered phase 3 clinical trials.

cls.cnFeb 17 11:21 ET

The seasonal influenza A has entered the epidemic period, and the sales of related Chinese Patent Medicine products have significantly increased.

① Recently, the positive rate of influenza virus has significantly increased, with over 99% being type A influenza. Market data shows a clear increase in the demand for various Traditional Chinese Medicine cold medicine products. ② Today, stock prices of several listed companies in the Traditional Chinese Medicine Industry, such as Shanxi Zhendong Pharmaceutical, Hainan Huluwa Pharmaceutical Group, and Zhongsheng Pharmaceutical, have reached the daily limit, with the Traditional Chinese Medicine Sector overall rising, and the Traditional Chinese Medicine 50 ETF increasing by 3.21%.

cls.cnJan 6 08:42 ET

Demand for vitamins has rebounded year-on-year. Tianxin Pharmaceutical states that changes in supply and demand have caused the price of folic acid to rise | Highlights from the earnings conference.

① The general manager of Tianxin Pharmaceutical, Yu Xiaobing, stated that there are signs of recovery in the vitamin market demand year-on-year in the second half of this year, and the changes in market supply and demand have led to an increase in the price of folic acid; ② The secretary of the board of directors of Tianxin Pharmaceutical, Dong Yi, answered questions regarding the fundraising projects.

cls.cnDec 3, 2024 04:45 ET